Vardenafil: A novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 4, 2004, Pages 923-932

  Kendirci, Muammer ^a   Bivalacqua, Trinity J ^a   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Corpus cavernosum; Erectile dysfunction; Nitric oxide; Pharmacokinetics

Indexed keywords

ALUMINUM OXIDE; ANDROGEN; ANTIFUNGAL AGENT; BLOOD CLOTTING FACTOR 7; CYCLIC GMP; CYTOCHROME P450 2C; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; DIGOXIN; ERYTHROMYCIN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MAGNESIUM HYDROXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; SILDENAFIL; TADALAFIL; TESTOSTERONE; UNINDEXED DRUG; VARDENAFIL;

BACKACHE; CARDIOTOXICITY; CLINICAL TRIAL; CROSS REACTION; DISEASE SEVERITY; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPEPSIA; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; IC 50; LONG TERM CARE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORGASM; PATIENT SATISFACTION; PRIAPISM; PROSTATE DISEASE; PROSTATECTOMY; RABBIT; REVIEW; RHINITIS; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SIDE EFFECT; SINUSITIS; ST SEGMENT DEPRESSION; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS; SULFONES; TRIAZINES;

EID: 1842832763     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.4.923     Document Type: Review

References (37)

1. FELDMAN HA, GOLDSTEIN I, HATZICHRISTOU DG, KRANE RJ, MCKINLAY JB: Impotence and its medical and psychosocial coRrelates: results of the Massachusetts Male Aging Study. J. Urol. (1994) 151(1)54-61.
2. AYTA IA, MCKINLAY JB, KRANE RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. (1999) 84(1):50-56.
3. LUE TF: Erectile dysfunction. N. Engl. J. Med. (2000) 342(24):1802-1813.
4. SEFTEL AD: Challenges in oral therapy for erectile dysfunction. J. Androl. (2002) 23(6):729-736.
5. BLANDER DS, SANCHEZ-ORTIZ RF, WEIN AJ, BRODERICK GA: Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. Int. J. Impot. Res. (2000) 12(3):165-168.
6. SAENZ DE TEJADA I, ANGULO J, CUEVAS P et al.: The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res. (2001) 13(5):282-290.
7. KIM NN, HUANG YH, GOLDSTEIN I, BISCHOFF E, TRAIS AM: Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase Type 5 inhibitor. Life Sci. (2001) 69(19):2249-2256.
8. BISCHOFF E, NIEWÖHNER U, HANING N, ES SAYED M, SCHENKE T: The inhibitory selectivity of vardenafil on bovine and human recombinant phosphodieasterase isoenzymes. Int. J. Impot. Res. (2001) 13(Suppl. 4):S41.
9. GBEKOR E, BS, FAWCETT L et al.: Phosphodiesterase 5 inhibitor profiles against all human phosphodiesterase families: Implications for use as pharmacological tools. J. Urol. (2002) 167(Suppl. 4):ABstract 967.
10. FRANCIS SH, CORBIN JD: Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr. Urol. Rep. (2003) 4(6):457-465.
11. CHOI S, O'CONNELL L, MIN K et al.: Efficacy of vardenafil and sildenafil in facilitating penile erection in an animal model. J. Androl. (2002) 23(3):332-337.
12. BISCHOFF E, NIEWOEHNER U, HANING H, ES SAYED M, SCHENKE T, SCHLEMMER KH: The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model. J. Urol. (2001) 165(4):1316-1318.
13. KLOTZ T, SACHSE R, HEIDRICH A et al.: Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: A RigiScan and pharmacokinetic study. World J. Urol. (2001) 19(1):32-39.
14. STARK S, SACHSE R, LIEDL T et al.: Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur. Urol. (2001) 40(2):181-188; Discussion: 189-190.
15. SACHSE R, RG, STARK S, KLOTZ T: Safety, tolerability and pharmacokinetics of BAY 38-9456 in patients with erectile dysfunction. J. Urol. (2000) 163:204.
16. RAJAGOPALAN P, MAZZU A, XIA C, DAWKINS R, SUNDARESAN P: Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J. Clin. Pharmacol. (2003) 43(3):260-267.
17. MAZZU A, TAYLOR T, BAUER R-J et al.: A single oral dose of vardenafil had no acute effect on sperm motility in healthy males. J. Androl. (2002) 23(Suppl. 1):2.
18. SHABSIGH R, KAUFMAN JM, STEIDLE C, PADMA-NATHAN R: Testosterone replacement therapy with testosterone gel 1% converts sildenafil non-responders in men with hypogonadism and erectile dysfunction who failed prior sildenafil therapy. AUA 2003 Annual Meeting, Chicago, Illinois, USA April 26 - May 1 (2003) (Abstract 954).
19. RADTKE M, KARL W, SEIDEL D, SCHNORBUS H, SCHREIBER A, BOBERG M: Biotransformation of [14C]-vardenafil in man. Drug Metab. Rev. (2001) 33(Suppl.):114.
20. STEIDLE C, PORST H, HOLLISTER A, SEGERSON T: Vardenafil demonstrated similar efficacy and tolerability among older and younger patients with marginal differences PK characteristics between age groups. Int. J. Impot. Res. (2001) 13:S63.
21. KLOTZ T, BAUER R-J, ROHDE G: Effect of renal impairment on the single-dose pharmacokinetics of vardenafil 20 mg, a selective PDE5 inhibitor for the treatment of erectile dysfunction. Pharmacotherapy (2002) 22:418.
22. ROHDE G, WENSING G, UNGER S: The pharmacokinetics of vardenafil, a new selective PDE5 inhibitor, are not affected by the antacid, Maalox 70. Pharmacotherapy (2001) 21(10):1254.
23. ROHDE G, JORDAN P: Influence of vardenafil on blood pressure and pharmacokinetics in hypertensive patients on nifedipine therapy. Pharmacotherapy (2002) 22:418.
24. MAZZU AL, NICHOLLS AJ, ZINNY M: Vardenafil, a new selective PDE-5 inhibitor, interacts minimally with nitroglycerin in healthy middle-aged male subjects. Int. J. Impot. Res. (2001) 13(Suppl. 5):S64.
25. ILSON BE, SHADDINGER BC, DABIRI GA et al.: A definitive study of the effects of PDE-5 inhibitors on cardiac repolarization in middle-age males. Clin. Pharm. Ther. (2004) 75:47.
26. BAUER R-J, ROHDE G, WENSING G: The interaction of alcohol with vardenafil, a potent and highly selective phosphodiesterase Type 5 inhibitor. Pharmacotherapy (2002) 22:418.
27. HELLSTROM WJ, GITTELMAN M, KARLIN G et al.: Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J. Androl. (2002) 23(6):763-771.
28. SAENZ DE TEJADA I, GLINA S, BECHER E, ULBRICH E, and the VARDENAFIL STUDY GROUP: Vardenafil exhibits long-term efficacy and safety for up to 52 weeks. Int. J. Impot. Res. (2002) 14(Suppl. 4):S22.
29. POTEMPA A-J, BERNARD I, ULBRICH E: Vardenafil improved erectile function in a 'real world' flexible-dose regimen. Int. J. Impot. Res. (2002) 14(Suppl. 4):S37-S61.
30. HATZICHRISTOU D, MONTORSI F, PORST H, BUVAT J, TAYLOR T, BANDEL T: A flexible dose regimen of vardenafil for erectile dysfunction; a placebo-controlled trial. Eur. Urol. (2003) Mar(Suppl. 2):176.
31. DONATUCCI C, KARLIN G, GOLDFISCHER E et al.: Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dysfunction. J. Am. Geriatr. Soc. (2002) 50(Suppl. 4):S107.
32. PORST H, ROSEN R, PADMA-NATHAN H et al.: Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function irrespective of the baseline severity and etiology of ED or age of patient. Eur. Urol. (2001) 39(Suppl. 5):17.
33. GOLDSTEIN I, GOLDSTEIN I, YOUNG JM et al., for the VARDENAFIL DIABETES STUDY GROUP: Vardenafil, a new phosphodiesterase Type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care (2003) 26(3):777-783.
34. BROCK G, NEHRA A, LIPSHULTZ LI et al.: Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J. Urol. (2003) 170(4 Pt 1):1278-1283.
35. PADMA-NATHAN H, PORST H, EARDLEY I, THIBONNIER M: Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Am. J. Hypertens. (2002) 15:48A.
36. KLONER R, MOHAN P, SEGERSON T, THIBONNIER M, NORENBERG C, PADMA-NATHAN H: Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: A post-hoc analysis of five placebo-controlled clinical trials. J. Am. Coll. Cardiol. (2003) 41:276A.
37. THADANI U, SMITH W, NASH S etal.: The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J. Am. Coll. Cardiol. (2002) 40(11):2006-2012.